Title: Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Infected Children Fungal Infections
1Guidelines for Prevention and Treatment of
Opportunistic Infections among HIV-Infected
ChildrenFungal Infections
- Recommendations from Centers for Disease Control
and Prevention, - the National Institutes of Health, the HIV
Medicine Association of - the Infectious Diseases Society of America, the
Pediatric Infectious - Diseases Society, and the American Academy of
Pediatrics
2About This Presentation
These slides were developed using the April 2008
Guidelines. The intended audience is clinicians
involved in the care of patients with HIV.
Users are cautioned that, because of the rapidly
changing field of HIV care, this information
could become out of date quickly. Finally, it is
intended that these slides be used as prepared,
without changes in either content or attribution.
Users are asked to honor this intent. Expert
opinion should be sought for complex treatment
regimens. AETC NRC
3Aspergillosis Epidemiology
- Aspergillus species are ubiquitous molds found in
soil, on plants, and in decomposing organic
materials - The most common species causing aspergillosis are
A fumigatus and A flavus - Rare but frequently lethal infection
- Risk factors include low CD4 count, neutropenia,
corticosteroids, concurrent malignancy with
chemotherapy, HIV-related phagocytic impairment,
previous respiratory infections, broad-spectrum
antibiotic exposure
4Aspergillosis Clinical Manifestations
- Pulmonary aspergillosis is the most common
presentation - Invasive pulmonary aspergillosis associated with
fever, cough, dyspnea, pleuritic pain - Additional manifestations include necrotizing
tracheobronchitis, pseudomembranous
tracheobronchitis, CNS involvement, cutaneous,
sinus, middle ear and mastoid infection
5Aspergillosis Diagnosis
- Usually isolated from the blood but also readily
isolated from lung, sinus, brain, and skin biopsy - Definitive diagnosis includes histopathologic
demonstration of organisms in biopsy specimens - Presumptive diagnosis of respiratory tract
infection can be made if Aspergillus species is
recovered from respiratory sample
6Aspergillosis Diagnosis (2)
- Chest radiograph demonstrates either diffuse
interstitial pneumonitis or localized
wedge-shaped infiltrates - CT of chest may be used to identify a halo sign
- Cavitation and air crescent formation in chest
CDT more frequent in older children and adults
7Aspergillosis Prevention
- Consider excluding plants and flowers from rooms
and avoiding food items such as nuts and spices - Erect suitable barriers between patient care and
construction sites, clean shower heads routinely
as well as hot-water faucets and air-handling
systems
8Aspergillosis Treatment
- Voriconazole is recommended for treatment of
invasive aspergillosis - Adult data indicate that voriconazole is superior
to amphotericin B but data in children are
limited - Recommended dosage for children is 6-8 mg/kg IV
(or 8 mg/kg orally) Q12H, followed by 7 mg/kg IV
or orally twice daily - Treatment is continued for 12 weeks
9Aspergillosis Adverse Effectsand Treatment
Failure
- Voriconazole side effects include reversible
dose-dependent visual disturbances, elevated
liver enzymes, and occasional skin rash - Amphotericin toxicity is associated primarily
with fever, chills, and nephrotoxicity - Efficacy of antifungal therapy for aspergillosis
is poor - Experimental approaches include evaluation of
caspofungin
10Candida Infections Epidemiology
- Most common fungal infections in HIV-infected
children - Thrush and diaper dermatitis occur in 50-85 of
HIV-infected children - In pre-ART era, oropharyngeal candidiasis found
in 94 of children with Candida esophagitis - Disseminated candidiasis rare in children except
those with CMV or HSV coinfection, and those with
central venous catheter
11Candida Infections Epidemiology (2)
- A substantial percentage of children with
fungemia receive oral, systemically absorbable
azole antifungals (eg, ketoconazole) - Complications include disseminated infection of
bone, liver, and kidney endophthalmitis - Mortality from disseminated candidiasis gt90 in
children with fever and symptoms gt14 days
12Candida Infections Clinical Manifestations
- Thrush and erythematous, hyperplastic, and
angular cheilitis - Esophageal candidiasis may present with
odynophagia, dysphagia, or retrosternal pain - Children may develop nausea, vomiting, or weight
loss and dehydration - New onset of fever in individuals with central
venous catheters - Systemic fungemia may lead to endophthalmitis
13Candida Infections Diagnosis
- Culture and KOH preparation with microscopic
demonstration of budding yeast cells in wet
mounts or biopsy - Blood culture using lysis centrifugation
- Cobblestone appearance on barium swallow
- Perform endoscopy in refractory cases to look for
CMV, HSV, MAC coinfections - Research studies or evaluating detection of
candidate antigens for early diagnosis
14Candida Infections Prevention
- Routine primary prophylaxis of candidiasis in
HIV-infected children is not indicated - Candida organisms are common commensals on
mucosal surfaces in healthy individuals and no
measures are available to reduce exposure
15Candida Infections Treatment
- Treat early uncomplicated oropharyngeal
candidiasis (OPC) with topical therapy - Cotrimoxazole 10 mg troches 4-5 times/day for 2
weeks (B II) - Nystatin suspension 4-6 mL (400,000-600,000
units/mL) 4 times/day - Amphotericin B suspension (100 mg/mL) 1 mL 4
times/day
16Candida Infections Treatment (2)
- Oral systemic therapy for OPC
- Fluconazole 3-6 mg/kg orally once daily for 7-14
days (A I) - Itraconazole 2.5 mg/kg orally BID for 7-14 days
(A I) - Ketoconazole 5-10 mg/kg/day orally divided into
2 doses given for 14 days (D II) - Amphotericin oral suspension or IV for OPC
refractory to other treatment
17Candida Infections Treatment (3)
- Esophageal disease
- Treat both diagnosed esophageal disease and
children with OPC and esophageal symptoms (A I) - Initiate treatment with
- Fluconazole 6 mg/kg/day orally or IV on day 1
followed by 3-6 mg/kg for 14-21 days (A I) - Itraconazole oral solution 2.5 mg/kg/dose given
twice daily or 5 mg/kg once daily for 14-21 days
(A I) - Consider low-dose IV amphotericin B minimum of 7
days for refractory disease (B II)
18Candida Infections Treatment (4)
- Esophageal disease
- Other therapies not fully evaluated in children
- Voriconazole loading dose of 6 mg/kg IV Q12H on
day 1, followed by 4 mg/kg Q12H thereafter after
stabilization, change to oral dosing - Caspofungin available only in IV form lt50 kg
dosage range 0.8-1.6 mg/kg daily gt50 kg, adult
dosing
19Candida Infections Treatment (5)
- Invasive disease
- Remove central venous catheter
- Amphotericin B (A I)
- 0.5-1.5 mg/kg once daily IV over course of 1-2
hours, administered in 5 dextrose at final
concentration of 0.1 mg/mL - For mild to moderate disease, begin at 0.25-0.5
mg/kg and increase as tolerated to 1.5 mg/kg - Once stabilized, administer 1.5 mg/kg every other
day(B III) - Treat for 3 weeks after last positive blood
culture of symptoms
20Candida Infections Treatment (6)
- Invasive disease alternative therapy
- Fluconazole in stable patients with uncomplicated
candidemia without previous azole treatment
(identification of Candida species essential C
krusei and C glabrata are resistant) (E III) - Amphotericin lipid formulations (limited
pediatric experience) - Amphotericin lipid complex (ABLC, Abelcet)
- Liposomal amphotericin lipid complex (AmBisome)
- Amphotericin B cholesteryl sulfate complex (ABCD)
21Candida Infections Treatment (7)
- Treatment under development
- Caspofungin, micafungin, and anidulafungin have
been studied in battles with HIV infection,
neutropenic children at risk of fungal infection
in children with documented candidiasis - Data on HIV-infected children are limited
22Candida Infections Treatment (8)
- Amphotericin toxicity
- Nephrotoxicity azotemia, hypokalemia
- Nephrotoxicity can be minimized by hydration with
0.9 saline intravenously 30 minutes before
amphotericin B infusion - Infusion-related chills, fever, and vomiting
pretreat with acetaminophen or diphenhydramine - Rarely hypotension, arrhythmias, neurotoxicity,
hepatic toxicity
23Candida Infections Treatment (9)
- Fluconazole, itraconazole, ketoconazole toxicity
- Inhibition of CYP450-dependent hepatic enzymes
can result in either decreased levels of azole
when administered with other drugs with hepatic
metabolism or increased levels of other drugs
with hepatic metabolism - Nausea, vomiting, rash, pruritus, Stevens-Johnson
syndrome (rare), increased liver enzymes,
hepatitis, leukopenia, anemia, hemolytic anemia,
alopecia (fluconazole)
24Candida Infections Treatment Failure
- Oral pharyngeal and esophageal candidiasis
- Initial failure should be treated with oral
fluconazole, itraconazole, oral amphotericin B,
or low-dose IV amphotericin B - Invasive disease
- Amphotericin B lipid formulations can be used for
children who cannot tolerate amphotericin B, have
disseminated Candida infection that is resistance
to amphotericin B, or are at risk of
nephrotoxicity
25Coccidioidomycosis Epidemiology
- Increased risk of infection with Coccidioides
immitis and Coccidioides posadasii among
HIV-infected children in endemic areas (eg,
southwestern United States, northern Mexico,
Central and South America) - Primary infection of newborn rare
- In utero and perinatal transmission ofC immitis
reported - Reports of infection in nonendemic areas usually
due to reactivation
26Coccidioidomycosis Clinical Manifestations
- Fever and dyspnea most common presentation
- Chills, weight loss, lymphadenopathy, chest pain,
diffuse reticulonodular pulmonary infiltrates,
meningitis - Disseminated disease associated with erythema
multiforme erythema nodosum erythematous
maculopapular rash arthralgia bone, joint, and
CNS infection
27Coccidioidomycosis Diagnosis
- Direct examination and culture of respiratory
secretions and CSF or biopsy of lesions - Blood cultures positive in 15 of cases
- Complement fixation assay detects IgG antibody,
positive IgM assays suggest active or recent
infection, complement fixation titers gt 116
correlate with presence and severity of
extrapulmonary infection
28Coccidioidomycosis Prevention
- Difficult to avoid exposure in endemic areas
- Exposure can be reduced by avoiding activities
that predispose to inhalation of spores such as
disturbing contaminated soil, being outdoors
during dust storms
29Coccidioidomycosis Treatment
- Limited data in children recommendations based
on adult data - Treat diffuse pulmonary disease or disseminated
disease with amphotericin B dosage of 0.5-1.5
mg/kg/day until clinical improvement occurs (A
II) - Follow with chronic suppressive fluconazole or
itraconazole therapy (A II) - Alterative therapy fluconazole 5-6 mg/kg BID or
itraconazole 4-10 mg/kg BID for 3 days followed
by 2-5 mg/kg BID (B III)
30Coccidioidomycosis Treatment (2)
- CNS infection, including meningitis
- High-dose fluconazole 5-6 mg/kg BID
- If unresponsive to fluconazole, use IV
amphotericin B augmented by intrathecal
amphotericin B (C I)
31CoccidioidomycosisMonitoring, Adverse Events
and Toxicity
- Monitoring of complement fixing IgG antibody is
useful - Toxicity of antifungal drugs includes fevers,
chills, nausea and vomiting, nephrotoxicity - Interaction of all antifungal agents with ARVs
should be investigated fluconazole and
itraconazole appear to be safe in combination
with ARVs - Voriconazole should be avoided in patients on PIs
or NNRTIs
32Cryptococcosis Epidemiology
- Most infections caused by Cryptococcosis
neoformans and Cryptococcosis gattii - Infection occurs primarily in tropical and
subtropical areas - Low incidence of infection in children,
especially with use of ART - Children usually infected during 6-12 year age
range - Usually severely immunosuppressed
33Cryptococcosis Clinical Manifestations
- Meningoencephalitis most common manifestation
- Fever, headache, altered mental status evolving
over days to weeks - Acute illness with nuchal rigidity, seizures,
focal neurologic signs observed in developing
countries - Translucent, umbilicated, papules, nodules,
ulcers, infiltrated plaques seen in disseminated
disease - Pulmonary cryptococcosis unusual in children
34Cryptococcosis Diagnosis
- Microscopic examination of CSF on India
ink-stained wet mounts - Detection of cryptococcal antigen in CSF, serum,
bronchoalveolar lavage fluid (can be negative in
culture-positive meningitis) - Fungal cultures from CSF, sputum, and blood
cultures can identify the organism - Antigen levels useful in evaluating response to
treatment and relapse - Pulmonary disease diagnosed by bronchoalveolar
lavage and direct examination of India
ink-stained specimens
35Cryptococcosis Prevention
- No proven strategies to prevent exposure
- Believed to be acquired by inhalation of
aerosolized particles from the environment
36Cryptococcosis Treatment
- Not well studied in children infection is often
fatal in the absence of treatment - CNS Disease
- Amphotericin B induction (0.7-1.5 mg/kg/day IV)
combined with 2 weeks of flucytosine (25
mg/kg/dose given 4 times daily) followed by
fluconazole for a minimum of 8 weeks - After symptoms are controlled, treat with
fluconazole or itraconazole maintenance - Use amphotericin B alone if flucytosine is not
tolerated - Fluconazole plus flucytosine is an alternative to
amphotericin B (limited data in children)
37Cryptococcosis Treatment (2)
- Pulmonary and extrapulmonary cryptococcosis
- No clinical trials on the outcome of non-CNS
cryptococcosis in HIV-infected patients - Treat with amphotericin B with or without the
addition of fluconazole (A III) - Fluconazole or itraconazole should be continued
long-term
38Cryptococcosis Monitoring and Drug Toxicity
- Amphotericin toxicity
- Nephrotoxicity azotemia, hypokalemia
- Nephrotoxicity can be minimized by hydration with
0.9 saline intravenously 30 minutes before
amphotericin B infusion - Infusion-related chills, fever, and vomiting
pretreat with acetaminophen or diphenhydramine - Rarely hypotension, arrhythmias, neurotoxicity,
hepatic toxicity
39Cryptococcosis Monitoring and Drug Toxicity (2)
- Flucytosine toxicity
- Bone marrow anemia, leukopenia, thrombocytopenia
- Liver, GI, and renal toxicity
- Fluconazole toxicity
- Potential interaction with ARV should be
evaluated before initiating treatment (A III)
40CryptococcosisIRIS and Treatment Failure
- IRIS related to cryptococcosis can present within
weeks - Optimal treatment of patients experiencing
treatment failure has not been defined - Patients failing initial azole treatment should
be switched to amphotericin B in combination with
flucytosine - Consider use of liposomal amphotericin B
- Experience with posaconazole or voriconazole is
limited
41Histoplasmosis Epidemiology
- Pathogen is Histoplasma capsulatum
- Incidence of disseminated histoplasmosis in
HIV-infected children in the United States is
lt0.4 - Incidence is higher in countries such as Brazil,
Argentina, and Mexico (2.7 to 3.8) - No evidence of dissemination of maternal
infection to the fetus or greater severity of
infection during pregnancy
42Histoplasmosis Clinical Manifestations
- Prolonged fever is the most common presentation
- Malaise, weight loss, and nonproductive cough
- Primary pulmonary focus leads to widespread
dissemination in children - Pulmonary manifestations common
- Physical findings include hepatosplenomegaly,
erythematous nodular coetaneous lesions, CNS
involvement with meningitis - Anemia, thrombocytopenia, elevated liver
transaminases - Progressive disseminated histoplasmosis (PDH) is
fatal if untreated
43Histoplasmosis Diagnosis
- Serologic testing using CF and immunodiffusion is
insensitive in the presence of HIV infection. - Positive in most patients but not useful for
diagnosis of acute infection - For diagnosis of CNS disease, a combination of
CSF antibody, antigen, and culture is most
sensitive - Skin testing not recommended for diagnosis
44Histoplasmosis Diagnosis (2)
- Culture of Histoplasma from blood or other
sources - Detection of H capsulatum polysaccharide antigen
in urine, blood, CSF, or bronchoalveolar lavage
using EIA - EIA sensitivity greater in disseminated disease
or acute pulmonary disease greater in urine than
in serum - Antigen levels decline with treatment and
correlate with both response to treatment and
relapse
45Histoplasmosis Prevention
- Most infections occur without a recognized
history of exposure - Sites and conditions commonly implicated include
outbreaks of soil contamination with bird or bat
droppings, older urban and rural structures, and
decaying vegetation
46Histoplasmosis Treatment
- Limited data for children recommendations based
on adult data - PDH is fatal without treatment and should be
treated with either amphotericin B or
itraconazole - Fluconazole has been used successfully as an
alternative for patients with mild disease and
for those who cannot tolerate itraconazole
47Histoplasmosis Treatment (2)
- Amphotericin B for patients with severe
disseminated disease requiring hospitalization
and for those who are immunocompromised - Amphotericin B induction dosage 1 mg/kg for 4-6
weeks followed by itraconazole chronic
suppressive therapy for 12 months (A I) - After successful treatment of acute disease, use
chronic lifelong suppressive therapy with
itraconazole - Liposomal amphotericin B alternative in event of
amphotericin B intolerance
48HistoplasmosisMonitoring and Adverse Effects
- Antigen levels should be monitored during
treatment and for 1 year thereafter - Adverse effects of amphotericin B include
nephrotoxicity, infusion related fever, chills,
nausea, and vomiting - Azole drugs inhibit CYP450-dependent hepatic
enzymes, warranting careful review of drug
interactions when using ARVs
49Pneumocystis jiroveci (carinii) Epidemiology
- Organisms are found worldwide in the lungs of
humans and lower animals - Antibody in 80 of normal children by 4 years
- Most common AIDS indicator disease in children
- Incidence highest in first year of life, peaking
at 3-6 months - Accounted for 57 of AIDS-defining illnesses in
infants age lt1 year pre-ART - CD4 T-cell count not a good indicator of risk in
infants lt1 year old - Infection now unusual owing to routine
prophylaxis with TMP-SMX
50Pneumocystis jiroveci (carinii)Clinical
Manifestations
- Fever, tachypnea, cough, dyspnea, poor feeding,
weight loss - Abrupt or insidious onset
- Bibasilar rales with evidence of hypoxia and
respiratory distress - Extrapulmonary locations spleen, liver, colon,
pancreas, ear, eye, GI tract, bone marrow, heart,
kidney, lymph nodes, CNS
51Pneumocystis jiroveci (carinii) Diagnosis
- Hypoxia with low arterial oxygen pressure
(alveolar-arterial oxygen gradient gt30 mmHg) - Definitive diagnosis requires demonstrating
organism - Induced sputum (difficult lt2 years)
- Bronchoscopy with bronchoalveolar lavage
- Fiberoptic bronchoscopy with biopsy generally
not recommended
52Pneumocystis jiroveci (carinii) Diagnosis (2)
- Open lung biopsy most sensitive
- Requires thoracotomy, chest tube drainage
- Organisms seen on biopsy with
- Gomori methenamine silver stain
- Toluidine blue stain
- Giemsa or Wright stain
- Monoclonal antibody
- DNA PCR for Pneumocystis MSG gene in fluids,
lavage sensitive but less specific than
histology
53Pneumocystis jiroveci (carinii) Prevention
- Need for isolation of hospitalized patients has
not been demonstrated, but when prophylaxis
cannot be given, may need to isolate patient or
susceptible contacts - Infants born to HIV-infected mothers should be
considered for prophylaxis at 4-6 weeks of age
and continued until 1 year of age (A II)
54Pneumocystis jiroveci (carinii) Prevention (2)
- Chemoprophylaxis with TMP-SMX recommended as
follows, based on CD4 counts and patient age - 6 years CD4 count lt200 cells/µL or CD4
percentage lt15 - 1 to 5 years CD4 count lt500 cells/µL or CD4
percentage lt15 - All HIV-infected infants lt12 months of age
regardless of CD4 count or percentage
55Pneumocystis jiroveci (carinii) Treatment
- TMP-SMX (A I)
- gt2 months 15-20 mg/kg/day of TMP component IV in
3-4 divided doses - Infuse over course of 1 hour
- Administer for 21 days
- Can be given orally in children with mild to
moderate disease - Lifelong prophylaxis indicated
56Pneumocystis jiroveci (carinii) Treatment (2)
- Adverse reactions
- Rash
- Stevens-Johnson syndrome (rare)
- Neutropenia, thrombocytopenia, megaloblastic or
aplastic anemia
57Pneumocystis jiroveci (carinii) Treatment (3)
- Pentamidine isethionate
- Recommended for patients with intolerance to
TMP-SMX or clinical failure with TMP-SMX (A I)
do not combine use - 4 mg/kg/day IV once daily over period of 60-90
minutes - Consider oral atovaquone after 7-10 days(B III)
58Pneumocystis jiroveci (carinii) Treatment
Alternatives
- Atovaquone (B I)
- Limited data in children
- 30-40 mg/kg/day divided into 2 doses, given with
fatty foods - Infants 3-24 months may require 45 mg/kg/day
divided into 2 doses, given with fatty foods (A
II) - Adverse reactions include rash, nausea, diarrhea,
increased liver enzymes
59Pneumocystis jiroveci (carinii) Treatment
Alternatives (2)
- Clindamycin/primaquine
- Used for mild to moderate PCP in adults no data
in children (C III) - Primaquine contraindicated in G6PD deficiency
60Pneumocystis jiroveci (carinii) Treatment
Alternatives (3)
- Clindamycin/primaquine
- Pediatric clindamycin dosing based on other uses
20-40 mg/kg/day IV divided into 3 or 4 doses,
administered for 21 days - Primaquine dosing based on malaria 0.3 mg/kg
daily of the base, administered orally for 21
days - Adverse reactions include rash, nausea, diarrhea,
pseudomembranous colitis
61Pneumocystis jiroveci (carinii) Treatment
Alternatives (4)
- Dapsone/TMP
- Use for mild to moderate PCP in adults no data
in children (C III) - Dapsone dosage lt13 years 2 mg/kg/day orally once
daily (A II) for 21 days - TMP 15/mg/kg/day orally divided into 3 daily
doses for 21 days - Adverse reactions include rash, anemia,
thrombocytopenia, increased liver enzymes
62Pneumocystis jiroveci (carinii) Treatment
Adjunct
- Corticosteroids
- Consider use in moderate to severe PCP
- Use within 72 hours of diagnosis
- Results in reduced respiratory failure, decreased
ventilation requirements, and decreased mortality
63Pneumocystis jiroveci (carinii) Treatment
Adjunct (2)
- Corticosteroids
- Dosing recommendations vary
- Prednisone 40 mg BID for 1-5 days 40 mg once
daily days 6-10 20 mg once daily days 11-21 - Alternative prednisone 1 mg/kg BID days 1-5 0.5
mg/kg BID days 6-10 0.5 mg/kg once daily days
11-21
64Pneumocystis jiroveci (carinii) Monitoring and
Adverse Events
- Short courses of corticosteroids have been used
in some cases of PCP of moderate to severe
intensity starting within 72 hours of diagnosis
(A I) - As with other coinfection, IRIS may occur
following initiation of ART but has been
described infrequently in PCP - Most common adverse reaction to TMP-SMX includes
rash and rarely erythema multiforme or
Stevens-Johnson syndrome - Pentamidine is associated with renal toxicity,
usually occurring 2 weeks after initiation of
treatment
65About This Slide Set
- This presentation was prepared by Arthur Ammann,
MD, Clinical Professor of Pediatrics University
of California and President of Global Strategies
for HIV Prevention for the AETC National Resource
Center, in July 2009 - See the AETC NRC website for the most current
version of this presentation - http//www.aidsetc.org